BlossomHill Therapeutics rallies $71m Series A

BlossomHill Therapeutics Inc, a biopharmaceutical company focusing on oncology and autoimmune disorders, has raised $71 million in Series A financing.

BlossomHill Therapeutics Inc, a biopharmaceutical company focusing on oncology and autoimmune disorders, has raised $71 million in Series A financing. The investors included Cormorant Asset Management, Hercules BioVentures Partners LLC, OrbiMed Advisors and Vivo Capital.

Source: Press Release